No price history available.
Key financial summary
Financials in RUB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | RUBm | 118,012 | 209,719 | N/A | N/A | 0 | N/A | N/A | N/A |
| Operating profit | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | RUBm | -68,415 | 5,743 | N/A | N/A | 11,400 | N/A | N/A | N/A |
| EPS reported | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in RUB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
PJSC Yakovlev, previously known as Irkut Corporation, is an aerospace enterprise engaged in the manufacturing and distribution of both military and civilian aircraft. The company also undertakes substantial research and development activities for these aviation platforms. Founded on October 13, 1992, its corporate headquarters are situated in Moscow, Russia. Yakovlev's operations are structured into several key business segments. The SU-30 Program focuses on the design, production, and delivery of SU-30 aircraft, their associated components, and necessary service equipment. Likewise, the YAK-130 Program is dedicated to the development, manufacturing, and provision of YAK-130 aircraft parts and support systems. A pivotal initiative is the MC-21 Program, which is centered on the creation of a novel civil aircraft featuring a silicon wing. Additionally, the Cooperation segment includes products that are jointly developed and produced in partnership with Airbus.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
PJSC Yakovlev, previously known as Irkut Corporation, is an aerospace enterprise engaged in the manufacturing and distribution of both military and civilian aircraft. The company also undertakes substantial research and development activities for these aviation platforms. Founded on October 13, 1992, its corporate headquarters are situated in Moscow, Russia. Yakovlev's operations are structured into several key business segments. The SU-30 Program focuses on the design, production, and delivery of SU-30 aircraft, their associated components, and necessary service equipment. Likewise, the YAK-130 Program is dedicated to the development, manufacturing, and provision of YAK-130 aircraft parts and support systems. A pivotal initiative is the MC-21 Program, which is centered on the creation of a novel civil aircraft featuring a silicon wing. Additionally, the Cooperation segment includes products that are jointly developed and produced in partnership with Airbus.